Home › Funds › BRAIDWELL LP › ACAD
BRAIDWELL LP position in ACAD
ACADIA PHARMACEUTICALS INC · Health Care
BRAIDWELL LP reported holding 1,646,399 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$41.7M, representing 1.64% of its reported portfolio and ranking #21 among its reported holdings. BRAIDWELL LP has disclosed ACAD holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's ACAD position evolved
BRAIDWELL LP first disclosed a stake in ACAD in Q3 2025 at 2,378,655 shares (US$50.8M). The position peaked in Q1 2026 at 2,471,199 shares, worth US$55.0M. Across 4 filings, BRAIDWELL LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,646,399 shares valued at US$41.7M — a reduction of -824,800 shares quarter over quarter.. Notable position changes include a 33% trim in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.38M | $50.76M | New |
| Q4 2025 | 2.03M | $54.28M | Reduce |
| Q1 2026 | 2.47M | $55.01M | Add |
| Q2 2026 | 1.65M | $41.65M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACAD and 13F data
ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.09B), RTW INVESTMENTS, LP (US$180.8M), Palo Alto Investors LP (US$72.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACAD
- BAKER BROS. ADVISORS LP 42.91M sh · $1.09B · Q2 2026
- RTW INVESTMENTS, LP 7.14M sh · $180.76M · Q2 2026
- Palo Alto Investors LP 2.86M sh · $72.46M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.44M sh · $36.39M · Q2 2026
FAQ
How long has BRAIDWELL LP held ACAD?
BRAIDWELL LP has disclosed ACAD holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is BRAIDWELL LP's current position in ACAD?
As of Q2 2026, BRAIDWELL LP holds 1.65M shares of ACAD (ACADIA PHARMACEUTICALS INC), valued at $41.65M, representing 1.64% of its reported portfolio and ranking #21.
Has BRAIDWELL LP been buying or selling ACAD?
In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in ACAD. The position peaked in Q1 2026 at 2.47M shares.
Which other funds hold ACAD?
Other major institutional holders of ACAD include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Palo Alto Investors LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.